Immatics N.V.

Immatics N.V. is a clinical-stage biopharmaceutical company that researches and develops T cell redirecting immunotherapies for cancer treatment in the United States. The company focuses on treating solid tumors using two treatment approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its product pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, currently in a Phase 2 trial. Other cell therapy products in development are IMA203CD8, in a Phase 1 clinical trial, and IMA204, which targets tumor stroma and is in a Phase 1 clinical trial. Additionally, Anzu-cel is being developed in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203) in a Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, both in Phase 1a clinical trials. Immatics N.V. has strategic collaborations with MD Anderson Cancer Center to develop T cell and TCR-based adoptive cellular therapies, with Celgene Corporation for novel adoptive cell therapies targeting multiple cancers, and with Genmab A/S for T cell engaging bispecific immunotherapies across multiple cancer indications. The company is headquartered in Tübingen, Germany.